Novartis Chief Sees Lasting Price Pressure as the New Reality
- Jimenez no longer sees leeway to raise drug prices in U.S.
- Swiss drugmaker to pool manufacturing operations to cut costs
This article is for subscribers only.
Novartis AG Chief Executive Officer Joe Jimenez figures the golden days of unfettered price increases are over in the U.S.
The soaring cost of some medicines has sparked a controversy that’s hampered drugmakers’ ability to raise prices in their biggest and most profitable market.